News & Press


Leading Skin Cancer Organizations Urge the FDA to Ban Tanning Beds for Minors

March 12, 2021

WASHINGTON, DC – The Melanoma Research Foundation (MRF) recently signed- on to a letter from the National Council of Skin Cancer Prevention (NCSCP) urging the U.S. Food and Drug Administration (FDA) to finalize the proposed rules entitled General and P …



FDA Grants Alkermes Orphan Drug Designation for the Treatment of Mucosal Melanoma

March 11, 2021

WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has recently granted orphan drug designation for the treatment of mucosal melanoma to Alkermes’ investigational engineered interleukin-2 (IL-2) variant immunotherapy, nemvaleukin alfa (“nemva …



130 Organizations Call to the President to Prioritize Cancer Patients and Survivors for COVID-19 Vaccine

February 19, 2021

WASHINGTON, DC – As concerns rise about the limited number of COVID-19 vaccines across the U.S., the Melanoma Research Foundation joined the American Association for Cancer Research (AACR) on a letter to President Joseph R. Biden, key members of his ad …



FDA Approves Foundation Medicine’s FoundationOne Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test

August 28, 2020

Washington, DC, August 28, 2020 – This week, the U.S. Food and Drug Administration (FDA) approved Foundation Medicine, Inc.’s comprehensive pan-tumor liquid biopsy test called FoundationOne Liquid CDx. This test analyzes more than 300 genes and genomic …



FDA Approves Atezolizumab to Treat BRAF V600 Unresectable or Metastatic Melanoma

July 31, 2020

Washington, DC, July 31, 2020 – On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresec …